Close Menu
The Business TimesThe Business Times
  • Home
  • News
  • Business
  • Finance
  • Economy
  • Markets
  • Investing
  • Real Estate
  • Crypto
  • Fintech
  • Forex
  • More
    • Politics
    • Web Stories
    • Spotlight
    • Press Release
What's On

Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript

22 September 2026

PGIM Quant Solutions International Equity Fund Q2 2026 Commentary

22 September 2026

Pain of NHS whistleblowers as call for Lucy Letby retrial grows louder

22 September 2026

Wealthfront Is Good Value As Further Rate Hikes Loom (NASDAQ:WLTH)

22 September 2026

Your Lunch Today Proves What The Fed Can’t Really Fix (NYSEARCA:SPY)

22 September 2026
Facebook X (Twitter) Instagram
Business Tuesday, Sep 22
The Business TimesThe Business Times
Newsletter
  • Home
  • News
  • Business
  • Finance
  • Economy
  • Markets
  • Investing
  • Real Estate
  • Crypto
  • Fintech
  • Forex
  • More
    • Politics
    • Web Stories
    • Spotlight
    • Press Release
The Business TimesThe Business Times
Home » DARREN LEWIS: 'Everyone should face scrutiny in Cambridge professor Jason Arday CV row'
News

DARREN LEWIS: 'Everyone should face scrutiny in Cambridge professor Jason Arday CV row'

thebusinesstimes.co.ukBy thebusinesstimes.co.uk10 August 20260 Views
Facebook Twitter LinkedIn Reddit Telegram WhatsApp Pinterest Tumblr VKontakte Email
Share
Facebook Twitter LinkedIn Pinterest Email

Having met the former Cambridge University professor, Darren Lewis knows he’s a decent person who will be aware that his conduct demands accountability. But let’s not forget the long list of people who’ve bent the truth about their past experience. While not wanting to suggest Arday should escape accountability, this points to a double standard

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram WhatsApp

Related Articles

Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript

PGIM Quant Solutions International Equity Fund Q2 2026 Commentary

Pain of NHS whistleblowers as call for Lucy Letby retrial grows louder

Wealthfront Is Good Value As Further Rate Hikes Loom (NASDAQ:WLTH)

Your Lunch Today Proves What The Fed Can’t Really Fix (NYSEARCA:SPY)

BrainsWay: Execution Isn’t The Problem, Market Size Is (NASDAQ:BWAY)

Pfizer: Stagnant Dividends At Rich Yields – Income Before Appreciation (NYSE:PFE)

George Risk Industries: Small In Size, Strong In Performance (OTCMKTS:RSKIA)

TriplePoint Venture Growth Offers A High Double-Digit Total Return Potential (NYSE:TPVG)

Editors Picks

PGIM Quant Solutions International Equity Fund Q2 2026 Commentary

22 September 2026

Pain of NHS whistleblowers as call for Lucy Letby retrial grows louder

22 September 2026

Wealthfront Is Good Value As Further Rate Hikes Loom (NASDAQ:WLTH)

22 September 2026

Your Lunch Today Proves What The Fed Can’t Really Fix (NYSEARCA:SPY)

22 September 2026

Subscribe to News

Get the latest finance and business news and updates directly to your inbox.

Latest Posts

BrainsWay: Execution Isn’t The Problem, Market Size Is (NASDAQ:BWAY)

22 September 2026

Pfizer: Stagnant Dividends At Rich Yields – Income Before Appreciation (NYSE:PFE)

22 September 2026

George Risk Industries: Small In Size, Strong In Performance (OTCMKTS:RSKIA)

22 September 2026
Facebook X (Twitter) Pinterest WhatsApp TikTok Instagram
© 2026 The Business Times. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.